Antigen-derived peptides engage the ER stress sensor IRE1α to curb dendritic cell cross-presentation
Author(s) -
Ofer Guttman,
Adrien Le Thomas,
Scot A. Marsters,
David A. Lawrence,
Lauren Gutgesell,
Iratxe Zuazo-Gaztelu,
Jonathan M. Harnoss,
Simone M. Haag,
Aditya Murthy,
Geraldine Strasser,
Zora Modrušan,
Thomas D. Wu,
Ira Mellman,
Avi Ashkenazi
Publication year - 2022
Publication title -
the journal of cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.414
H-Index - 380
eISSN - 1540-8140
pISSN - 0021-9525
DOI - 10.1083/jcb.202111068
Subject(s) - cross presentation , endoplasmic reticulum , unfolded protein response , antigen , biology , antigen presentation , epitope , microbiology and biotechnology , major histocompatibility complex , cd8 , antigen processing , mhc class i , t cell , antigen presenting cell , cytotoxic t cell , immune system , immunology , biochemistry , in vitro
Dendritic cells (DCs) promote adaptive immunity by cross-presenting antigen-based epitopes to CD8+ T cells. DCs process internalized protein antigens into peptides that enter the endoplasmic reticulum (ER), bind to major histocompatibility type I (MHC-I) protein complexes, and are transported to the cell surface for cross-presentation. DCs can exhibit activation of the ER stress sensor IRE1α without ER stress, but the underlying mechanism remains obscure. Here, we show that antigen-derived hydrophobic peptides can directly engage ER-resident IRE1α, masquerading as unfolded proteins. IRE1α activation depletes MHC-I heavy-chain mRNAs through regulated IRE1α-dependent decay (RIDD), curtailing antigen cross-presentation. In tumor-bearing mice, IRE1α disruption increased MHC-I expression on tumor-infiltrating DCs and enhanced recruitment and activation of CD8+ T cells. Moreover, IRE1α inhibition synergized with anti–PD-L1 antibody treatment to cause tumor regression. Our findings identify an unexpected cell-biological mechanism of antigen-driven IRE1α activation in DCs, revealing translational potential for cancer immunotherapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom